{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '3. Evaluate the effect of teprotumumab versus placebo on the overall responder rate at', 'Week 24 stratified by the level of response (high responders, responders, low responders,', 'and non-responders; see Section 9.6.4.3.1 for definitions).', '4. Evaluate pharmacokinetic (PK) parameters of teprotumumab to estimate exposure and', 'understand PK-PD relationships.', '5. Mean change from Baseline to Week 24 in the GO-QoL questionnaire VF and A subscale', 'scores.', '6. Evaluate the effect of teprotumumab on the mean change from Baseline to Week 24 in', 'blood and serum biomarkers.', '7. Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to', 'Week 24 on the motility component of the Clinical Measures of Severity.', '9.6.2 Populations for Analysis', 'The following analysis populations will be defined for this study:', 'Intent-to-Treat (ITT)', 'Modified Intent-to-Treat (MITT) population', 'Per Protocol (PP) population', 'Safety Population', 'The ITT population will include all subjects who are randomized to treatment. Full details of the', 'analysis populations will be described in the SAP.', '9.6.3 Primary and Secondary Endpoint Analysis', 'The primary analyses will be conducted in the ITT population. The analysis of the primary', 'proptosis responder endpoint will assess risk difference (difference in response rates) in a', 'stratified analysis. The analysis will use Cochran-Mantel-Haenszel (CMH) weighting to estimate', 'the common risk difference within strata and to estimate the standard error of the common risk', 'difference. Subjects missing the Week 24 evaluation will be considered to be treatment failures', '(non-responders) for the primary analysis. Further, subjects who prematurely discontinue study', 'drug dosing prior to Week 21 during the double-masked Treatment Period will be considered to', 'be treatment failures (non-responders), unless an assessment at Week 24 is available.', 'Stratification for the analysis will use the same factor as was used to stratify randomization,', 'tobacco use (non-user, user). The difference in response rates, comparing teprotumumab to', 'placebo, will be estimated along with the corresponding 95% confidence interval (CI) and', 'p-value.', 'An analysis of risk difference with stratification by tobacco use (non-user VS. user) will also be', 'used to analyze the 3 secondary categorical endpoints. For the analysis of proptosis and GO-QoL', '(see Section 9.6.4.4 for details) as continuous secondary endpoints, a Mixed-Model Repeated-', 'Measures (MMRM) analysis of covariance (ANCOVA) model will be fit to the individual', 'change from baseline scores for the study eye, with terms in the model being the baseline score,', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 103 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'tobacco use status, treatment group, visit, and the visit-by-treatment and visit-by-baseline-score', 'interactions. The main focus of the analysis will be to test the treatment differences at Week 24,', 'with the main results consisting of the Week 24 estimated Least Square (LS) means and their', 'differences with 95% CIs and p-values.', 'To control the overall Type 1 error rate of the study, taking into consideration the one primary', 'and 5 secondary outcome measures, the outcome measures will be tested in a hierarchical', 'stepwise fashion. For each outcome measure, teprotumumab will be tested against placebo at the', '0.05 level only if teprotumumab was statistically significant for the outcome measure preceding', 'it in the hierarchical order.', '9.6.4', 'Exploratory Analyses', '9.6.4.1 Pharmacokinetics/Pharmacodynamics', 'All PK data and parameters will be presented descriptively, including arithmetic means, standard', 'deviations, geometric means, CVs, medians, and ranges. The key data are Ctrough plasma levels at', 'Week 9 prior to infusion and at Week 24, important to confirm that plasma concentrations were', 'maintained above the 20 g/ml level through the course of the dosing period.', 'The relationship between clinical endpoints and the plasma concentrations of teprotumumab will', 'be explored in a descriptive manner.', '9.6.4.2 Clinical Measures of Severity', 'The Clinical Measures of Severity results (see Table 9.3) for each item will be summarized at', 'each designated visit for each eye with the number and percentage of subjects being classified as', 'responders on each individual criterion. The proportions of responders will be analyzed using the', 'same risk difference method described for the primary endpoint in Section 9.6.3.', '9.6.4.2.1 Motility Component of the Clinical Measures of Severity', 'The monocular ductions of the study eye (degrees) will be compared between the 2 treatment', 'groups at each evaluation period for adduction, abduction, supraduction and infraduction.', 'For each motility measure, the analysis of the changes from baseline in the target eye will be', 'conducted using the same MMRM ANCOVA analysis as the continuous secondary endpoint', 'analysis in Section 9.6.3, substituting the appropriate baseline assessments.', '9.6.4.3 Clinical Activity Score (CAS)', 'CAS will be measured as a continuous variable using the MMRM ANCOVA model described', 'above to compare the treatment groups.', '9.6.4.3.1 Stratification of Proptosis and CAS Response into Four Responses Categories', 'To further explore the response based on both proptosis and CAS reduction, each subject will be', 'classified into one of 4 response categories at Week 24:', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 104 of 117']\n\n###\n\n", "completion": "END"}